SCHEMBL3808468

SCHEMBL3808468

COC(=O)c1cc2cc(NCc3cc(NC(=O)c4ccc(CN5CCN(C)CC5)cc4)ccc3C)cnc2[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 17/20 0.58
▸ SRC P12931 12/20 0.58
▸ LCK P06239 4/20 0.58
▸ EGFR P00533 3/20 0.58
▸ BCR P11274 3/20 0.58
▸ FYN P06241 2/20 0.58
▸ LYN P07948 2/20 0.58
▸ BRAF P15056 2/20 0.58
▸ PDGFRA P16234 2/20 0.58
▸ FRK P42685 2/20 0.58
▸ YES1 P07947 1/20 0.58
▸ HCK P08631 1/20 0.58
▸ CSF1R P07333 3/20 0.49
▸ DDR2 Q16832 2/20 0.49
▸ KDR P35968 2/20 0.49
▸ MAPK14 Q16539 2/20 0.49
▸ ERBB4 Q15303 1/20 0.49
▸ KIT P10721 2/20 0.47
▸ PLK4 O00444 1/20 0.47
▸ DDX3X O00571 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15859835 0.93 ABL1 (0.51) ABL1SRCLCKEGFRBCR
SCHEMBL15859886 0.92 ABL1 (0.51) ABL1SRCLCKEGFRBCR
SCHEMBL15860018 0.92 ABL1 (0.57) ABL1SRCLCKEGFRBCR
SCHEMBL15859833 0.92 ABL1 (0.50) ABL1SRCLCKEGFRBCR
SCHEMBL13261092 0.90 ABL1 (0.53) ABL1SRCLCKEGFRBCR
SCHEMBL15860001 0.90 ABL1 (0.57) ABL1SRCLCKEGFRBCR
SCHEMBL15859979 0.89 ABL1 (0.69) ABL1SRCLCKEGFRBCR
SCHEMBL15860120 0.89 ABL1 (0.50) ABL1SRCLCKEGFRBCR
SCHEMBL13260700 0.89 ABL1 (0.56) ABL1SRCLCKEGFRBCR
SCHEMBL15859903 0.88 EGFR (0.60) ABL1SRCLCKEGFRBCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9403823-B2 Protein kinase inhibitors ORIBASE PHARMA (FR) 2016-08-02 — — US disclosed
US-20160009709-A1 PROTEIN KINASE INHIBITORS ORIBASE PHARMA (FR) 2016-01-14 — — US disclosed
EP-2396325-B1 DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC ORIBASE PHARMA (FR) 2015-04-01 — — EP disclosed
US-8580815-B2 Derivatives of azaindoles as inhibitors of protein kinases ABL and SRC ORIBASE PHARMA (FR) 2013-11-12 — — US disclosed
US-8580815-B2 Derivatives of azaindoles as inhibitors of protein kinases ABL and SRC ORIBASE PHARMA (FR) 2013-11-12 — — US disclosed
US-20110312959-A1 Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC ORIBASE PHARMA (FR) 2011-12-22 — — US disclosed
US-20110312959-A1 Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC ORIBASE PHARMA (FR) 2011-12-22 — — US disclosed
EP-2396325-A1 DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC OriBase Pharma (FR) 2011-12-21 — — EP disclosed
WO-2010092489-A1 DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC NOVA DECISION (FR) 2010-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009709-A1 PROTEIN KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K2 ABL1 128/4885SRC 199/4885LCK 24/4885
US-20110312959-A1 Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC ABL1, ABL2, SRC ABL1 1/4885SRC 3/4885LCK 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback